Genaissance Pharmaceuticals, Trangenomic, Cepheid, Infectio Diagnostics, Orchid Biosciences | GenomeWeb

Genaissance Posts Mild Growth in Q3 Atop Increases in R&D, Loss

Genaissance Pharmaceuticals reported a modest increase in third-quarter revenue amid greater R&D spending and a slight jump in net loss.

Total revenues for the period ended Sept. 30 increased to $2.6 million from $1.8 million one year ago. R&D spending in the quarter also jumped to $6 million from $4.7 million year over year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.